SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " regulating " 72 found 🔀 AI-powered Shuffle
Scientists discover a promising blood sugar–regulating compound in red alga
It is a dietary staple found in sushi, rice wraps and ramen toppings. Commonly known as nori in Japan and gim in Korea, red seaweed is especially popular across Asia. Yet, despite its widespread consumption, ...
Yale School of Medicine On the Science of Childhood Anxiety, Say, Anxiety Disorders Are the Most Common Mental Health Challenges In Youth
Credit: Matt Bradbury October 5, 2026 - By Isabella Backman - Anxiety disorders are the most common mental health challenges in youth. Left untreated, they can disrupt the lives of both children and their families. The good news is that with intervention, most children will overcome these conditions. Across Yale School of Medicine, scientists are working to understand anxiety at every level, from common anxious behaviors to molecular biomarkers in the brain. They are using their findings to develop and disseminate new evidence-based treatments for childhood anxiety. Today, the go-to treatment for childhood anxiety disorders is cognitive behavioral therapy (CBT). This is a form of psychotherapy that teaches children skills for confronting anxious thoughts and helps them practice managing situations that cause anxiety. While it is the gold-standard treatment backed by considerable scientific evidence, up to 50% of children will not see sufficient benefit from CBT alone. Wendy Silverman, PhD, Alfred A. Messer Professor in the Child Study Center, co-directs the Anxiety and Mood Disorders Program alongside Eli Lebowitz, PhD, associate professor in the Child Study Center. One of their main interests is learning how to improve outcomes beyond CBT. “We’re developing cutting-edge, research-based knowledge that can reduce the suffering that anxiety causes children and their families,” says Silverman. Changing parent behavior YSM experts are investigating how to improve CBT outcomes for children by involving the parents. Silverman’s research has uncovered two main components of parent intervention that improve childhood anxiety: not enabling children to completely avoid the things that make them anxious and taking steps to enhance their autonomy. Parents may unintentionally reinforce their child’s anxiety by allowing them to avoid what makes them anxious. They also may unintentionally limit the children’s sense of autonomy by being overly intrusive. “One of the things that we take pride in is that we’ve focused on trying to understand what parents need to do, and to test our ideas and see if changing the parents’ behaviors is enhancing the effects of CBT,” Silverman says. “Our findings thus far suggest that they do." As much as CBT can be helpful, it can also be challenging to get one’s child to do the necessary steps for CBT to work. This is one important reason why Lebowitz created a novel intervention program for parents named Supportive Parenting for Anxious Childhood Emotions (SPACE). Existing intervention programs often teach parents to act as therapists for their child, such as training them on how to practice breathing exercises. “It makes sense, but this doesn’t work very well in practice,” says Lebowitz. “And part of the reason, I think, is that it’s not easy to get your kid to do things, especially if they’re not excited about doing it.” SPACE is unique because it focuses entirely on parent involvement and changing parental behavior—children are not involved in the sessions. For example, parents learn how to use supportive messages that convey confidence that their child can tolerate and manage distress. “It might sound like a parent saying to a child, ‘I get that this is really hard for you, but I know that you can handle it,’” Lebowitz says. The program also works with parents to identify the ways in which they are accommodating anxious behaviors. “We’ll pick one thing that parents are doing that is an accommodation and help them make a detailed plan for how they’re going to change that,” Lebowitz explains. Treating Anxiety in Children and Adolescents Much of the existing research on SPACE has focused on parents of children under age 14. Ongoing studies are now exploring its use with parents of older teens. “Both anxiety and accommodation can interfere with normative developmental shifts during the teen years, including increased autonomy and individuation from parents,” says Rebecca Etkin, PhD, associate research scientist in the Child Study Center. “In this sense, SPACE may be particularly well-suited for anxious teens and their parents. We want to see whether it is effective during this distinct developmental window.” Unfortunately, many families in need of CBT face barriers, including limited availability of services and geographic constraints. One way to improve access is digital interventions. Silverman and her team are developing an evidence-based digitized intervention program for parents that they can access directly from their computer or smart phone. “The work we’re doing will be one of the very few parent interventions that is digitized and importantly tested for effectiveness,” she says. Creating interventions for anxiety-related challenges Silverman and Lebowitz recently received a generous gift to develop and test other interventions that help parents reduce other child anxiety-related behavioral and emotional difficulties, such as restrictive eating and unexplained somatic symptoms. One of these projects in particular focuses on understanding the risks of social media and its potential benefits, including offering a sense of connection. “A lot of research has focused on the idea that social media is harmful and the less of it the better,” says Lebowitz. “But we actually see is that this is not quite right—there are negatives, but there are also positives. So, we’re trying to get a little bit more nuanced of a picture.” The team is working with teens with social anxiety and their parents over an extended period to better understand their social media habits and how their anxiety levels affect engagement with different platforms. The teens will answer questions sent to an app on their phones about mood and social media usage in an effort to capture emotional responses as they unfold. “We hope to develop interventions that can help make the best of social media while protecting against the more problematic effects,” Lebowitz says. The brain’s role in anxiety Researchers are also testing therapies to address anxiety at the neurological and molecular levels. In collaboration with Dylan Gee, PhD, professor of psychology in Yale's Faculty of Arts and Sciences, and Hilary Blumberg, MD, John and Hope Furth Professor of Psychiatric Neuroscience at Yale School of Medicine, Lebowitz and Silverman are using brain imaging to identify changes in a child’s brain before and after parents enroll in SPACE. In one study, children viewed anxiety-inducing images while undergoing magnetic resonance imaging (MRI); the researchers conducted scans with and without the children’s parents nearby. Before SPACE, children’s brains were better able to activate the regulatory circuitry needed to turn off an anxious response when their parents were nearby. But after SPACE, children could activate this circuitry even without the parent around. “As parents work on gradually reducing some of their accommodations, you can see a child get better at regulating their own fear system in the brain,” Lebowitz says. “It’s remarkable.” Research into the molecular underpinnings of anxiety can also inform new childhood anxiety treatments. In a recent study, Lebowitz, Silverman, and Flora Vaccarino, MD, Harris Professor in the Child Study Center, discovered that a protein known as fibroblast growth factor 2 (FGF2) could be protective from the toxic effects of stress. FGF2 levels in children and their parents were linked to the children’s risk of developing anxiety and depression, the study showed. The findings could help explain why some children who are exposed to early life trauma such as poverty or abuse are more prone to developing mental health disorders. And FGF2 could be a target for treatment. “This is very novel because it starts to give a clue to what is the molecular chain that connects those lived experiences to the actual psychological outcomes,” Lebowitz says. New ways to study and treat childhood anxiety Michael Crowley, PhD, associate professor in the Child Study Center, collaborates with Silverman and Lebowitz to study the role that attention plays in development and maintenance of childhood anxiety. There is a large body of research that shows that anxious children, like anxious adults, are prone to focus on threatening stimuli such as angry faces compared with neutral faces. This has led to innovative interventions that involve attention retraining. The idea is that if experts train children to look away from threatening stimuli, it may reduce their anxiety—especially children with social anxiety who are most prone to attend to threats. The researchers have just completed a clinical trial for attention retraining with 10- to 14-year-olds with social anxiety disorders and are currently analyzing the findings. Besides this innovative attention retraining research, as Crowly notes, “I like to design tasks that are engaging to kids,” Crowley says. “My goal is to assess something without the kids knowing what we are assessing.” With this goal in mind, Crowley has created a virtual game, named Boom, to study threat processing in children with anxiety disorders. The game is similar to that of hot potato—the child and three digital players take turns virtually passing a ball to each other’s gloves. At some point, the ball turns into a bomb, and as the bomb lands in each player’s glove, the outline of the glove turns yellow. The goal is to avoid having the bomb go off in your glove. What isn’t obvious is that the game is designed to measure different types of threatening stimuli, both ambiguous and direct. In the game, the direct threat occurs as the bomb is traveling towards your glove. The ambiguous threat is the yellow outlined glove as it is unknown where the bomb will travel next. While children play the game, Crowley’s team measures their brain activity using electroencephalography (EEG). The researchers have discovered that in kids with anxiety, the brain reacts more strongly to ambiguous threats than it does in their peers, but less strongly to direct threats. They believe that the initial abnormally large brain response to not knowing where the bomb is going impairs the brain's ability to properly respond when the threat is actually traveling the child’s way. “The brains of children with anxiety are unable to differentiate between threats you need to do something about and those that are not your problem.” Michael Crowley, PhD, develops innovative games for studying anxiety in children and adolescents.Credit: Matt Bradbury Based on these insights, Crowley hopes to study whether interventions like attention training could restore appropriate threat processing. Crowley’s team is also working on a test called the Balloon Risk Avoidance Task, which evaluates risk-taking and avoidance behaviors. It features a digital balloon that is full of air and about to burst. Kids have six seconds to let air out of the balloon. The more air they let out, the less risk they face that the balloon will pop. But at the same time, the balloon becomes less valuable as it deflates. “The more air you keep in the balloon, the more points you get,” Crowley explains. So far, the researchers have found that when the balloons pop unexpectedly, teens with social anxiety show distinct brain responses. Studying these responses can help psychologists understand the underlying pathways driving the various manifestations of anxiety. The genetics of anxiety When Thomas Fernandez, MD, associate professor in the Child Study Center and of psychiatry, was still in training, there was a lot of excitement about understanding the genetics associated with autism spectrum disorder. Since then, scientists have identified around 250 genes associated with autism. The genetic contribution to anxiety disorders, on the other hand, has historically received less attention. Anxiety is less heritable than autism, but the genetic contribution for anxiety disorders that emerge in childhood may be higher than for anxiety disorders overall. While scientists estimate the heritability of anxiety disorders in general to be around 30% to 50%, some studies suggest higher heritability for certain childhood-onset anxiety presentations. “I saw firsthand how researchers in the field went about finding vulnerability genes for autism,” Fernandez says. “So, we’re using a very similar playbook for childhood anxiety.” “I saw firsthand how researchers in the field went about finding vulnerability genes for autism. So, we’re using a very similar playbook for childhood anxiety.” Thomas Fernandez, MD Associate Professor In the Child Study Center and in Psychiatry Now, Fernandez and Emily Olfson, MD, PhD, assistant professor in the Child Study Center, are studying children and their parents to identify genetic changes that are present in the child but not the parents, known as “de novo mutations.” “All of us have some de novo mutations—maybe about 50 to 100 sprinkled throughout the genome,” Olfson says. “But when they occur within the coding regions of genes, they can be really disruptive.” Previous research shows that people with autism have higher rates of damaging de novo mutations than the general population. In 2022, Olfson, Lebowitz, Silverman, and Fernandez published a study on 68 children and their families that found that children with anxiety had similarly high levels of these mutations. Studying de novo mutations can help point the researchers to where they should be looking for genes associated with anxiety. “The end game is using the genes to steer us toward the right part of biology that we can then target to come up with better treatments,” Fernandez says. Building on those findings, the team is now studying more families to better understand how these de novo mutations, along with other genetic and environmental factors, shape pediatric anxiety disorders. They recently received a National Institutes of Health grant to enroll 750 new families over the next five years. Olfson is the principal investigator, with co-investigators Lebowitz, Fernandez, Silverman, and Shuangge Steven Ma, PhD, department chair and professor of biostatistics at Yale School of Public Health. Neurodevelopment, Risk Genes, and Mental Health Conditions - The Olfson Lab Joel Gelernter, MD, Foundations Fund Professor of Psychiatry, is interested in how different anxiety disorders differ genomically. “We are studying social phobia, panic disorder, and generalized anxiety disorder, working to understand why people differ in their risk to these specific anxiety disorders and evaluating various risk factors,” he says. Gelernter was recently involved in one of the largest studies to date of the genomics underlying anxiety disorder. The study included around 122,000 people with anxiety disorders and around 730,000 without. It found that some genetic differences associated with anxiety were linked to signaling that helps reduce overactivity in the nervous system. Many anxiety medications available today work by targeting this process. “It’s nice when the biology that you get out of a large genome-wide study ratifies things that we already know because that can help increase confidence in further findings from the study,” Gelernter says. Uncovering the neurobiology of psychiatric disorders John Krystal, MD, Robert L. McNeil, Jr. Professor of Translational Research and chair of the Department of Psychiatry, is interested in the neurobiology of psychiatric disorders, including post-traumatic stress disorder (PTSD), of which anxiety is a major symptom. In the late 1980s, Krystal’s team discovered that the drug yohimbine activated symptoms in patients with PTSD. “This was the first time we could link a specific biological mechanism to the symptoms of PTSD,” Krystal says. At the time, he adds, this finding was highly controversial. “A lot of people felt that PTSD was a purely psychological syndrome that didn’t have an underlying biology.” Since then, Krystal has dived deep into understanding the neurobiology of PTSD to learn how to better treat it. His team is evaluating the use of ketamine and psychedelics. These would be among the first treatments to be developed specifically for PTSD. They may also be applicable for other disorders including anxiety disorders, Krystal adds. An important gap in PTSD treatment is the absence of biological tests that inform how to best help patients manage their PTSD symptoms. A doctor doesn’t diagnose cancer based on how they feel. Rather, they use tests of the biology of the cancer to determine the best course of treatment. “And we can’t do that in any psychiatric disorder other than Alzheimer’s disease,” Krystal says. “But now we are building a foundation for this approach to the treatment of anxiety disorders for the first time.” Source: Yale School of Medicine
Republicans and Democrats find a unifying target: Pharmacy benefit managers
Republicans and Democrats, both patients and politicians, seem united in their disdain for the healthcare companies known as pharmacy benefit managers. Tennessee and Arkansas are regulating them now.
Fareed Zakaria on his takeaways from top tech meeting and what’s difficult about regulating AI
Lina Khan says AI companies shouldn't follow Big Tech's playbook
Former FTC chair Lina Khan cautioned against AI companies regulating themselves during an interview on ABC's "This Week."
Brazil is regulating AI use in elections. Here’s why it’s been a challenge.
Brazil’s polarized political landscape is rife with disinformation – a challenge that can be turbocharged by artificial intelligence.
Would-be Pelosi successors debate who’s more progressive in San Francisco congressional race
In the race to succeed Nancy Pelosi, the candidates clashed over who will be most aggressive in regulating AI and who is closest to organized labor
Editorial: The Trump administration’s strange affection for prediction markets
There is something genuinely strange happening at the Commodity Futures Trading Commission, the federal agency responsible for regulating derivatives markets. Under Chairman Michael Selig, the CFTC has challenged states seeking
Senate tees up college sports bill aimed at regulating NIL deals
The Senate is due to vote Monday on the bill, which would create a national framework for name, image and likeness deals in college athletics.
How political tensions over Trump family crypto ventures derailed Clarity Act
President Trump and his family’s sprawling empire of cryptocurrency businesses cast a long shadow over efforts this year to negotiate a bill regulating the industry. They arguably weighed down bipa…
‘Powerful and beautiful’: Here’s why we all need body fat
From releasing hormones to regulating our temperature, fat has myriad roles in the body. Here’s how much you need and why chasing extreme fat-loss goals is unhealthy.
‘Powerful and beautiful’: Here’s why we all need body fat
From releasing hormones to regulating our temperature, fat has myriad roles in the body. Here’s how much you need and why chasing extreme fat-loss goals is unhealthy.
The Habit You Should Start for Better Liver Health, Recommended By Experts
For liver health, experts say sit less! It promotes a healthy liver by building muscle, keeping you active and regulating metabolism and blood sugar.
Appeals court rules that states can regulate Kalshi’s sports prediction markets, dealing another legal blow to platforms
The decision is the second in less than a month by an appeals court that states have a role in regulating sports-related event contracts.
Trump and Johnson meeting with AI executives set for Tuesday
President Donald Trump and Speaker Mike Johnson (R-LA) will meet with executives of top AI companies at the White House on Tuesday, the Washington Examiner confirmed. The expected meeting underscores the pressure Republicans are under to regulate the industry ahead of the November midterm elections. Johnson has rejected calls to act quickly on regulating AI models, […]
Why did an OpenAI system hack Australia's health system - and can it be stopped in the future?
News that an automated AI agent hacked a government IT system raises big questions about regulating the tech.
The potential local impact of Spanberger's data center 'framework'
Gov. Abigail Spanberger released her blueprint for regulating data center development last week, billing it as “a new way forward for how this industry does business in the Commonwealth.”
California and Texas announce restrictions on data center development
California Gov. Gavin Newsom and Texas Gov. Greg Abbott are regulating data center development amid bipartisan backlash.
Protect College Sports Act passes first vote in Senate; minority groups oppose bill
A bill aimed at regulating college sports took an important step towards becoming official this week, even as minority groups continue to oppose the bill.
Why Steve Bannon sided with Sanders, not Trump, on AI
Where does Steve Bannon fit in the debate over regulating or slowing AI? He tells Morning Edition where he breaks with Trump and what he thinks Washington should do.
Lancaster County lawmakers support regulating Flock cameras
Across Lancaster County, video cameras are recording the license plates of passing cars, along with their vehicle make, model and paint color, and storing that information in searchable databases.
Iowa communities grapple with regulating data centers as development spreads
As data center development spreads across to Iowa, at least six cities and 10 counties are considering policies to regulate the industrial use. Several local governments have enacted moratoriums, ranging from three months to 18 months, as officials draft ordinances to govern the developments and their impact on resources while also allowing for economic growth. …
Kimmel says interview with James Talarico won't air on TV under pressure from the FCC
Jimmy Kimmel says the federal agency regulating television has "threatened" his show | WBEN
Kimmel says interview with James Talarico won't air on TV under pressure from the FCC
Jimmy Kimmel says the federal agency regulating television has "threatened" his show. An interview with James Talarico, a Democratic candidate for U.S. Senate in Texas, will now air on YouTube instead...
Kimmel says interview with James Talarico won't air on TV under pressure from the FCC
Jimmy Kimmel says the federal agency regulating television has "threatened" his show.
Four Japanese scientists win prestigious U.S. Lasker Awards
One received the prize for his work on a sleep-regulating brain chemical, and a trio, for discovering an antibody therapy for hemophilia A patients.
Trump again appeals to Supreme Court on mail voting restrictions as midterms loom
The Trump administration on Thursday asked the Supreme Court to reject an order by a federal judge that halts it from implementing a new rule regulating mail ballots, hours after being unable to tell that judge whether the computer system that would govern the entire project was operational yet.
Antarctic expedition reveals why Southern Ocean clouds remain one of climate science's greatest challenges
The Southern Ocean plays a pivotal role in regulating Earth's climate, yet the clouds that blanket this remote region remain among the least understood features in atmospheric science. By controlling ...
Video in competitive congressional race spotlights challenge of regulating AI-generated political content
In Wisconsin, a recent example can be found on the campaign social media of U.S. Rep. Derrick Van Orden, R-Prairie du Chien, who is running a competitive reelection bid.
Wisconsin congressman violates 'spirit' of state law regulating AI in campaigns
In the days leading up to and after the Wisconsin primary, Congressman Derrick Van Orden was posting AI-generated videos of his opponent Rebecca Cooke online.
FDA promises new AI guidance, and what happened at Epic's UGM
In this edition of STAT Health Tech: FDA's plans for regulating generative AI-powered devices, and updates from EPIC's UGM.
The Limits of Unauthorized-Practice in Regulating Mental Health AI - Petrie-Flom Center
In May, Pennsylvania’s State Board of Medicine filed a lawsuit in the state’s Commonwealth Court against Character Technologies seeking to prevent it from engaging in unauthorized medical practice. The alleged “practitioner,” however, was not a physician or even a human being. It was a chatbot named Emilie.
Trump admin. attempts to stop states from regulating online prediction markets
The Trump administration is attempting to block New York and other states from regulating online prediction markets.
Viewpoint: Europe needs a new scientific contract
The White House's new science strategy should be required reading in the Berlaymont and every European capital.Not because Europe should copy it. Parts of it should concern Europeans deeply. But because it asks the question Europe has so far avoided while steadily losing ground in the global race for technological leadership.Europe already possesses many of the world's finest universities, scientists and research-intensive companies. It produces world-leading research in fields ranging from quantum technologies and biotechnology to climate science. Yet time and again Europe generates the scientific breakthroughs while others build the companies, industries and strategic advantages around them, particularly in digital technologies. Increasingly, we find ourselves regulating technologies whose underlying capabilities were developed elsewhere.This is not primarily a scientific failure. It is an institutional one.The settlement that shaped modern science policy emerged after the Second World War. In Science, the Endless Frontier, Vannevar Bush argued that governments should invest in fundamental research while protecting scientists from political direction. Public investment was justified precisely because no government, university or company could predict where the next transformative discovery would emerge.That scientific contract served liberal democracies extraordinarily well. It underpinned decades of advances in medicine, computing, energy and communications, but the world for which it was designed no longer exists.Artificial intelligence is transforming not only technology but the production of knowledge itself. Advanced chips, computing power, data and scientific instruments have become strategic assets. Scientific knowledge now diffuses globally almost instantly. Competitive advantage increasingly lies not in making discoveries first, but in possessing the infrastructure, capital, engineering capability and institutions required to translate those ideas into products, industries and strategic advantage.The old boundaries between science, industrial policy, national security and geopolitics have largely disappeared. Dual-use technologies now underpin both economic power and military deterrence.The US has recognised this shift. In July, the White House published Science: A New Golden Age, a comprehensive attempt to rethink the relationship between science and national power. The report builds on Bush's legacy, but departs from his framework in important ways. Science is no longer treated simply as the source of future discoveries. It is presented as the foundation of economic resilience, technological leadership and national security. AI, advanced infrastructure and the capacity to build become as important as discovery itself.Yet the report also reveals a striking paradox. The same administration calling for “a new golden age” of US science has simultaneously proposed deep cuts to the federal research enterprise while expanding political influence over the allocation of public research funding. Europe should therefore distinguish between the report's diagnosis and its prescription. The diagnosis, that science has become a strategic asset, is compelling. But the prescription is self-defeating. Long-term technological leadership depends on strong universities, academic freedom and the institutional autonomy that makes scientific discovery possible. This distinction matters. Bush's achievement was never simply to make science serve national strength. It was to establish a division of labour in which governments invested in research without attempting to direct discovery itself. Scientific breakthroughs emerge precisely because researchers retain the freedom to pursue questions whose value cannot yet be demonstrated and whose conclusions cannot be anticipated.Neither China, nor the USAs science becomes more strategically important, the temptation to politicise it inevitably grows. But scientific freedom is not an obstacle to technological leadership, it is an essential precondition.China represents the opposite model. For decades it has integrated science, manufacturing, infrastructure and industrial policy into a single national strategy. Its ability to mobilise resources around critical technologies is formidable. But it does so within an authoritarian system where scientific priorities are increasingly inseparable from political power.Europe should imitate neither model. It should learn from the strategic ambition of the US without importing its growing politicisation of science. And it should learn from China's capacity to build without adopting its concentration of power.Instead, Europe needs a scientific contract of its own. Bush's scientific contract protected the freedom to discover because the defining challenge of the 20th century was producing new knowledge. Europe's next scientific contract must preserve that freedom while ensuring that scientific discoveries can be converted into technological, industrial and strategic capability. Because in a transactional world, Europe's freedom to shape its own future depends on its capacity to build it.Related articlesThe US ‘golden age’ science strategy: what Europeans need to knowEuropean researchers sound the alarm that Trump rule changes will hit cooperationNIH turmoil risks reciprocal EU-US access to health research fundingThis does not mean subordinating free science to competitiveness or industrial policy. On the contrary. Scientific autonomy remains the first principle of Europe's next scientific contract. Governments should not direct scientific discovery. Their responsibility is to ensure that Europe's scientific, industrial, financial and regulatory institutions work together rather than in isolation.Meeting that responsibility requires far more than research funding. European researchers need access to world-class computing infrastructure, advanced laboratories, shared datasets and scientific facilities. Innovative companies need patient capital, testing environments and a genuine single market in which they can scale without facing 27 different regulatory regimes. Public procurement must evolve from purchasing existing technologies to creating markets for new ones. Regulators must become partners in experimentation rather than guardians of yesterday's rules.A connecting architectureEurope does not need to invent the Defense Advanced Research Projects Agency (Darpa) model from scratch. Britain's Aria, Germany's Sprind and Wellcome Leap already show that Europe can build institutions capable of taking high-risk, mission-oriented bets while preserving democratic accountability. The challenge now is not to create more isolated initiatives, but to connect them to Europe's broader scientific, industrial and financial system so that breakthrough discoveries can scale.Above all, Europe must stop treating research, innovation, industrial policy, finance and security as separate policy domains. The challenge is no longer to create excellent institutions in each of these fields, but to make them work as one European innovation system. Europe's strength will increasingly depend not on excellence within institutions, but on excellence across them.Europe's ambition should be neither to imitate the US nor to emulate China. It should demonstrate that scientific freedom, democratic legitimacy and technological capability are not competing objectives, but mutually reinforcing strengths. In an age of geopolitical rivalry, Europe's greatest advantage may ultimately be its ability to attract the world's best talent by combining scientific freedom, democratic openness and technological ambition.Bush's scientific contract helped define the 20th century because it protected the freedom to discover. Europe's challenge is not to abandon that achievement but to extend it. The defining task of Europe's next scientific contract is to preserve the freedom to discover while building Europe's capacity to translate scientific discovery into technological power.Kaare Nielsen is founder of Pomus, a Danish think tank on science and innovation.
Trump administration plans to upend Head Start by deregulating it
The administration is preparing a rollback of Head Start, a change that supporters of the childcare program fear could gut its long-held anti-poverty mission.
Trump Administration Plans to Upend Head Start by Deregulating It
The White House tried but failed to block funding for preschool for poor children. Instead, it will seek to strip away standards on health, literacy — and brushing teeth.
U.S. states are all over the map on how to regulate AI therapy chatbots
Six states have split four ways on regulating AI therapy chatbots. The same product can be legal in one place and criminally exposed in another
Federal appeals court hears Maine test case on regulating super PACs
The U.S. Supreme Court’s landmark decision that struck down limits on independent political spending does not need to be overturned to rein in Big Money in politics, Neal Katyal argued before the U.S. Court of Appeals for the First Circuit in Boston on Wednesday in defense of Maine’s 2024 referendum regulating political spending.
44 states are aligned on one thing in their fight against prediction markets. It's about sports wagering
The letter is part of the commission’s public comment period for the first draft of its proposed rule on regulating prediction markets.
Can state-regulated hemp THC businesses continue under Schedule 1?
Hemp THC products lose federal protections in November, but states may continue regulating the products like they did with cannabis.
How to Regulate AI Without Stifling Health Innovation
LDI experts discuss the current landscape and questions around regulating clinical AI systems on the state- and federal-levels.
California doesn’t need to put an ‘Out of Business’ sign on AI innovation
California should be leading the AI revolution, not regulating itself onto the sidelines.
Trump regulator orders Kalshi to defy Michigan court – escalating battle over prediction markets
The Trump administration took an extraordinary step this week to escalate its nationwide efforts to prevent states from regulating prediction markets, where users can trade on real-world events like sports, politics and pop culture.
When regulation is good for business
By now, I think I have established both my view that I am a fan of ESG investing and the benefits of regulating what is and isn’t a sustainable investment, and my view that in Europe, ESG regulation has gone too far and become too costly. It almost feels like the old Aristotelian maxim of doing things in moderation that leads to the best outcomes is valid in regulatory efforts as well. To give you an example, let’s look at a study by the National Bank of Belgium on the impact of the EU’s Sustainable Finance Disclosure Regulation (SFDR) on fund flows of conventional and ESG funds. The SFDR was announced on 27 November 2019 and came into effect on 10 March 2021. It was implemented in several stages and split funds marketed in the EU into three broad categories: (i) Art. 6 funds that are basically conventional funds without any specific ESG integration, (ii) Art. 8 funds that ‘promote environmental or social characteristics’, which must provide additional reporting how they do that, and (iii) Art. 9 funds that are impact funds. The gaps between the announcement and the phased implementation give us an idea of how fund flows were affected by the regulation. It is clearly visible in the figure below that once the new regulation was announced and when it was initially implemented, fund flows in Art. 8 and Art. 9 funds increased significantly. Conventional Art. 6 funds also saw more inflows, but the increase was not statistically significant. I should add that the data below is pure fund flow, cleaned of performance effects and of any reclassified funds that moved from one classification to another. Note also that once the initial rush in ESG funds was over, additional, stricter regulatory requirements didn’t create that many new flows. This implies that with additional regulation, the funds incurred higher costs to comply but didn’t benefit in terms of new inflows and higher assets under management. Fund flows as the SFDR regulation was implemented in the EU Source: Emiris et al. (2026) When examining the drivers of these flows, the authors of the study found that institutional investors were more likely to switch to ESG funds and particularly so in countries where concerns about sustainability are culturally more accepted. In a society where buy-in into environmental and social risks is higher, private investors were shifting more of their assets into ESG funds as the regulation made it clear which funds are really green and which ones are not. And institutional investors in these countries did so as well, given the societal pressures and reputational risks of sticking with conventional funds. Meanwhile, fund managers reacted to the changing regulatory environment as well. Many funds that were mildly green before the regulation was announced became greener and more sustainable as the regulation was introduced to attract new assets and new investors. Cleverly, and unsurprisingly, these ESG funds also charge on average higher fees, which means that not only did fund managers gather fresh assets, but their profitability increased as well.
Columbia scientists discover surprising link between serotonin and heart valve disease
Scientists have uncovered evidence that serotonin, the chemical best known for regulating mood, may also speed the progression of a common heart valve disease in some people. The research suggests that patients with degenerative mitral regurgitation who take SSRI antidepressants and carry a specific genetic variant may develop severe valve damage sooner, potentially requiring surgery at a younger age.
RFK Jr. wants to make it easier to get peptides. FDA scientists disagree.
The health secretary has advocated for deregulating certain peptides, but FDA scientists point to a lack of data about their safety and effectiveness. Some have not been studied in humans.
Making Our Own Luck
We are cross-posting a piece that former NIH official Kris Willis wrote for Macroscience. Kris is now the President and Founder of the Woodley Park Institute, for which I’m a board member. Picking winners or hedging bets? Federal science agencies have long wrestled with the question of how to ensure their billions of dollars of grants and contracts result in maximum benefits for Americans. On the surface, it might seem that a goal-oriented, interventionist style of management would be the best policy: prioritize our most pressing problems and distribute funding accordingly.This top-down strategy creates a unique hazard, though: bad choices can send resources in the wrong direction, resulting in slow progress that impedes the delivery of tangible benefits to citizens. Moreover, if decision makers pursue an applied advance when the underlying scientific principles remain poorly understood, they risk costly failures and a loss of support for the research enterprise at large. Examples include Nixon’s 1971 War on Cancer, undertaken on the premise that a cure could be achieved in less than a decade, the drive to build an operational commercial fusion plant by the mid-1990s, and the National Plan to Address Alzheimer’s Disease, which failed to produce the effective treatments and prevention strategies promised by 2025. The contrasting laissez-faire approach is to hedge your bets. If the path to an advance is impossible to predict, then the wisest choice might be to distribute funding to as widely as possible. The main risk of this strategy is that spreading funding thinly may limit the resources available to the most promising research, resulting in the same negative outcomes as the interventionist approach: limited support for the most promising topics, slow progress, and delayed returns. In reality, at science agencies like the National Science Foundation and National Institutes of Health, program managers navigate between these two extremes, setting some funds aside to target high-priority areas and using the rest to cover the widest possible range of meritorious proposals. This middle path seems like the most rational way to proceed, but it still requires making choices. How much should be set aside for high priority topics? What should those topics be? How should we define merit? Expert opinion can provide a helpful guide, but leading experts can have remarkably different opinions about what matters and what should be prioritized. Moreover, experts and administrators alike can be risk averse, giving an edge to high-profile, well-established concepts. What’s really needed is a data-driven framework to help guide decision-making, one that doesn’t simply repackage prestige or incumbency. Recognizing breakthroughs years in advance Many breakthroughs fail to attract funding or recognition at the earliest stages of development. Katalin Karikó, for example, spent years struggling to win grants for work on mRNA that would eventually win her and Drew Weissman a Nobel Prize. Similar stories can be told about Jim Allison’s groundbreaking studies leading to the development of cancer immunotherapy, Stan Pruisner’s demonstration that prions can self-replicate without DNA, or Robin Warren and Barry Marshall’s proof that Helicobacter pylori, not stress, causes ulcers. Yet at some point, the scientific community recognizes and responds to transformative breakthroughs like these. How does that change happen? And what if science funders could identify the areas that are on the cusp of a breakthrough? Those questions led my collaborators and me to study how scientists responded to past breakthroughs. Based on patterns in that data, we developed a means of predicting future breakthroughs, using biomedicine as a proof of concept. It’s worth taking a moment to describe how our approach works. Briefly, our prediction process begins by grouping the 18 million or so peer-reviewed papers in PubMed, the authoritative database of biomedical research, into roughly 50,000 unique topics. A small subset of these topics are so widely acclaimed as breakthroughs that they have been recognized with a major prize like a Nobel or a Lasker Award. We theorized that studying the development of these outliers over time, especially before they gained acclaim, was the key to identifying future instances of them. After defining topics, we chose 21 representative breakthroughs and asked what they looked like before they won prestigious prizes. To answer that question, we re-ran our topic-mapping algorithm repeatedly, winding back the clock one year each time, stringing together the years to follow the progress of each field as it grew and advanced. We found that in each case, the years leading up to a discovery followed a pattern: a burst of papers on a new, rapidly evolving topic, many of which quickly became influential. These characteristics—the percent of papers that are new, the percentage of papers that are brought in from other topics, and the influence of each individual paper—can all be measured separately for any given topic. Together, they act as a predictive signal that is detectable an average of five years before a transformative discovery is made, and up to thirty years before the discovery receives a major prize. Scanning the current research landscape for topics that display this signal allows us to predict what work will likely produce a future breakthrough. Each year we analyzed includes four or five signals, a number that appears to have remained constant across a twenty year time frame. In their classic work on the sociology of science, Bruno Latour and Steve Woolgar established that the desire to participate in a major discovery is an important motivator for scientists as they consider whether they should take up (or abandon) a research problem. Although further work is needed, the simplest explanation for our results is that this behavior is widespread enough to detect at scale. A foundational advance, or something like it, draws the attention of scientists and causes them to change the direction of their research. They vote with their feet, staking their own reputation and careers by publishing on and citing the new idea. That upswell of interest is the foundation of our breakthrough signal. What kind of research does our model identify as a breakthrough? After building a model based on the patterns in our 21 preselected breakthroughs, we tested it by identifying all early signals of discovery from 1994 through 1997. Of the 18 signals we found in that time period, 17 can be traced forward in time to a breakthrough. Examples include super-resolution fluorescence microscopy (see the image above), the directed evolution of proteins and enzymes (Chemistry Nobel, 2018), and sequencing the human genome (National Medal of Science, 2008). The discovery of the role of leptin signaling in obesity is a particularly interesting case study. Around 1950, scientists noticed the existence of a type of lab mouse that suffered from a unique inherited form of obesity. When given the freedom to choose their own diet, these mice ate more than normal and preferred food that was high in fat. Researchers had few clues as to why the animals overate; early experiments pointed to the existence of a soluble ob factor found circulating in the bloodstream that regulated appetite, but its identity was unknown. In 1994, Jeffrey Friedman and colleagues identified and sequenced the ob gene, noting that the protein it encoded appeared to fit the profile of a circulating factor. A year later, a trio of high-profile publications demonstrated that ob was a hormone that regulated body weight and fat deposition by regulating appetite. One of these was co-authored by Friedman, who christened it leptin from the ancient Greek word for thin. Using our model, the data from 1996 make it clear this advance would become a breakthrough. Scientists had flocked to study the biology of the new hormone, generating the flurry of new papers and citations required to produce a signal. One of these demonstrated that serum leptin concentrations reflected the amount of adipose tissue in the human body, providing clinical validation of the earlier mouse studies. Before the identification of leptin, scientists were unable to point to a specific molecule that controlled appetite and adiposity, so that it was impossible to rule out non-physiological causes of obesity; its characterization fundamentally changed our concept of weight gain. In 2010, Friedman and fellow pioneer Douglas Coleman were awarded a Lasker for the discovery. Our work also identifies breakthroughs in clinical practice and behavioral and social sciences, even though these areas are less likely to draw the attention of major prize committees. One example that falls into this category is the introduction of endovascular aneurysm repair, a minimally invasive surgical procedure for the treatment of abdominal aortic aneurysm, a leading cause of death among Americans over the age of 65. Relative to the previous standard of care, it reduces in-hospital mortality by almost four-fold. In 2017, Timothy Chuter received the American College of Surgeons’ prestigious Jacobsen Innovation award for his multiple refinements to the technique. Another under-recognized breakthrough identified by our model is the development of standardized survey instruments to assess the quality of life for HIV+ patients. The antiretroviral cocktails introduced in the mid-1990s reduced AIDS mortality, but treatment came with serious side effects. The new evaluations showed that patients whose disease progressed had worse physical functioning than Americans with other chronic diseases, while those who were asymptomatic maintained a health-related quality of life on par with the overall US population. This evidence made it possible for patients and activists to argue that even in the absence of a total cure, and in spite of the side effects, alleviation of symptoms was a worthwhile priority for clinicians. My colleagues and I have failed to identify any significant recognition for the physicians and health policy experts who pioneered this advance, although in 2016, researchers called for the World Health Organization to set targets for good health-related quality of life as part of its framework to end the AIDS pandemic. From forecasting to funding How should science funders use our predictions? Any serious discussion of what we should do with this new capability needs to begin with an understanding of its limitations. We can’t (and shouldn’t) invest all of our resources in the small number of topics predicted to produce breakthroughs. Innovative new fields are born from existing ones; they rarely arise de novo. If funders don’t maintain a diverse portfolio, the breakthroughs of tomorrow will have no antecedents. Think of this as eating the seed corn, or killing the goose that lays the golden egg. There are also multiple goals of funding beyond basic scientific discovery, including translating discoveries into clinical practice, developing new technologies, supporting economic development, and training new scientists. The investments needed to accomplish these goals are likely different from those required to support emerging breakthroughs. Finally, we must be aware that we may not capture every instance of a breakthrough. The concept is fuzzy, and not every significant discovery is recognized with a major award. Further, breakthroughs are rare, meaning that our dataset is, by necessity, small. This makes formal estimates of accuracy challenging. Although our overall success rate appears to be high, any one signal may turn out to be a false positive. We found one apparent example: the development of the third generation COX-2 inhibitors, Vioxx and Celebrex, which were much celebrated in the early 2000s as effective but non-addictive pain relievers, meets all the algorithmic criteria of a breakthrough. Five years after it received FDA approval, researchers demonstrated that Vioxx was associated with serious cardiovascular complications, and the manufacturer voluntarily pulled the drug from the market. Celebrex remains available, although like other NSAIDs, it carries an FDA warning for increased cardiovascular risk. Decision makers who were overly focused on the breakthrough potential of this research might have wasted substantial resources nurturing an area that ultimately proved to be a failure—but so would those who relied on expert opinion at the time. That said, the potential benefits of funding the next mRNA vaccine or cancer immunotherapy years earlier than we might have are large. When we can’t assume the outcome of an action, it’s worth conducting an experiment. Can targeted support for areas that are poised to produce a breakthrough increase the return on scientific investment without cannibalizing future advances? With the necessary administrative infrastructure in place, conducting this experiment would be straightforward. First, identify all the breakthrough signals between 2018 and 2023, select half at random, and commit to a decade of investment. For biomedicine, a six year window should yield about 30 topics with the potential to produce a breakthrough. Providing strong support to half of these might be accomplished for $300 million a year. That’s roughly half of the recent annual budget of the NIH Common Fund or around 20% of the fiscal year 2025 budget for ARPA-H. After five years, then again at ten, compare to see which group — the one that was actively managed, or the control — produced more breakthroughs, and on what timescale. Although we used biomedicine as an example, the same experiment could just as well be run for physics, materials science, or any other discipline. Any attempt to undertake such an experiment should keep three points top of mind. First, we can predict the topic of future breakthroughs, but the people and vision for how to move the work forward are still important. In practice, this means success requires active program managers with the expertise to develop the science and the authority to do so, including by recruiting investigators. Second, we would be wise to learn from the failures of past attempts to fund transformative research. High among these are funding modestly repackaged work, confusing the genuinely novel with the merely unfamiliar, and relying too much on incumbent investigators. All of these risks can be mitigated by thoroughly and intelligently integrating high quality data into portfolio management. Finally, we need to have patience. Even with strong funding support, producing a breakthrough takes time. If supporting breakthroughs is the best way to nurture the birth of new fields, we also need to accurately describe and properly manage the other two stages, so that we invest wisely throughout the productive lifetime of ideas and divest once they reach the point of diminishing returns. We would benefit from more study of all of these phases, especially the transition from one to another. More research could answer questions like: When does a breakthrough become an established field? How do the availability of funding, the size and characteristics of the available workforce, and the accumulation of evidence that disagrees with prevailing models affect a field’s decline? Exactly how do old ideas give birth to new ones, and can we speed up the process? The more we understand about the dynamics of scientific progress, the better we can maximize the odds that our curiosity leads to results. I’d call that finding a way to make our own luck.
AI regulation is a mess, and Anthropic is caught in the crosshairs
The latest spat between Anthropic and the government raises a broad concern among AI and safety researchers: There is no consistent framework for regulating AI.
Beneath our feet lies a fungal superhighway stretching 68 quadrillion miles
Beneath our feet lies a vast hidden fungal superhighway that helps sustain much of life on Earth—and scientists have now mapped it for the first time. Researchers estimate that these underground networks stretch an astonishing 110 quadrillion kilometers, move about 4 billion tons of carbon dioxide into soils each year, and play a major role in supporting plants and regulating the climate.
Former CFTC Chair Gary Gensler on regulating sports betting: Let the states do it
Gary Gensler, former CFTC chairman under President Obama and former SEC chairman under President Biden, joins 'Squawk Box' to discuss why he's filing an amicus brief arguing Congress did not intent to make the CFTC the nationwide regulator of sports betting when it passed the Dodd-Frank Act in 2010, regulating sports betting, his thoughts on prediction markets, insider trading concerns, and more.
Decoding AI: Oklahoma Gov. Kevin Stitt on regulating AI in political ads: ‘We want to make sure voters aren’t confused’
How to Improve Your Gut Health (and Why It’s So Important)
Almost 40% of Americans say their daily lives are affected by their bowel habits so Dr. Trisha Pasricha, author and a director of gut-brain research, joins TODAY to break down why gut health is so important. She explains how your gut is responsible for regulating metabolism, immune health, and mood, highlights signs to know if your gut is healthy, and shares ways to improve gut health like eating more fiber.
Granberg joins advisory group to Trump’s college sports roundtable
A University spokesperson said Granberg is participating in an advisory group of college presidents to Trump's Saving College Sports roundtable which is advocating for reforms in collegiate athletics, like regulating the process by which student-athletes earn money and establishing structured rules for the transfer portal and NCAA eligibility.
Amendments to the Code Regulating Health Worker Mobility Were Adopted at the World Health Assembly. Now What?
At the 79th World Health Assembly, Member States adopted landmark amendments to the World Health Organization’s (WHO) Global Code of Practice on the International Recruitment of Health Personnel. But what were these changes, and how can they be operationalised in practice?
SCORE Act aims to change NCAA sports, how college coaches are hired and fired
As the SCORE Act regulating NCAA athletics makes its third attempt to move through Congress, this version aims to tackle coaches' hiring cycles.
Gov. DeSantis signs legislation more tightly regulating data centers
The Governor said the new law gives local governments control over land use rules to protect from data centers.
Amid NIL tumult, Florida mulls regulating college sports agents
The possibilities in Florida include capping the cut agents can take from athletes, adding new registration requirements and even charging them a fee to prove they’re legitimate business representation.
Regulating the Mississippi River: Where art and science meet
When Dan Fasching started painting again after a decade, he said it was because it was something near and dear to his heart. His muse? The Mississippi River that he works on every day.
Listen: With Little Federal Regulation, States Are Left To Shape the Rules on AI in Health Care
As artificial intelligence embeds itself into health care, some physicians and patient advocates worry it could be used by insurance companies to refuse payment for care. Maryland passed one law banning AI from acting alone on a denial. Meanwhile, Virginia’s then-governor vetoed that state’s attempt at regulating AI in health insurance.
The 'Healthy Choice Waiver' is not about health — it’s about controlling the poor
Regulating the behavior of those already struggling does not address public health issues.
States want to limit AI in health insurance
Regulating artificial intelligence, especially its use by health insurers, is becoming a politically divisive topic.
Online sports betting petitions cleared for circulation after more than a month of waiting
The final language for two petitions aimed at legalizing and regulating online sports betting in Nebraska has been approved and the petitions are now ready for circulation.
Tuberville: Elected PSC members are ‘politicians looking for their next job’
“Those regulating public utilities should answer to the people directly,” former U.S. Sen. Doug Jones countered.
Regulating Digital Health Technologies
Randi Seigel examines the evolving regulatory landscape for digital health tools.
Scientists warn climate models are missing a key ocean player
Tiny marine plankton that build calcium carbonate shells play an outsized role in regulating Earth’s climate, quietly pulling carbon from the atmosphere and helping lock it away in the deep ocean. New research shows these microscopic engineers are largely missing from the climate models used to forecast our planet’s future, meaning scientists may be underestimating how the ocean responds to climate change.
A Secret Panel to Question Climate Science Was Unlawful, Judge Rules
The researchers produced a report a that was central in a Trump administration effort to stop regulating climate pollution.
Scientists find ‘master regulator’ that could reverse brain aging
Researchers have identified OTULIN, an immune-regulating enzyme, as a key trigger of tau buildup in the brain. When OTULIN was disabled, tau vanished from neurons and brain cells remained healthy. The findings challenge long-held assumptions about tau’s necessity and highlight a promising new path for fighting Alzheimer’s and brain aging. Scientists now believe OTULIN may act as a master switch for inflammation and age-related brain decline.
How new protest laws are impacting political demonstrations
More than a dozen states have passed laws regulating protests in recent years, raising concerns among free-speech advocates.
Why your vitamin D supplements might not be working
A new randomized trial from Vanderbilt-Ingram Cancer Center reveals that magnesium may be the missing key to keeping vitamin D levels in balance. The study found that magnesium raised vitamin D in people who were deficient while dialing it down in those with overly high levels—suggesting a powerful regulating effect. This could help explain why vitamin D supplements don’t work the same way for everyone and why past studies linking vitamin D to cancer and heart disease have produced mixed results.
How the Trump administration is recasting government’s role in regulating health technology
Federal agencies that used to set up guardrails for health technology have transformed into cheerleaders for new risky technologies like AI.
NCAA-backed effort to reshape college sport regulations has hit a wall in Congress
House Republicans plans to vote on a bill regulating college sports has been scrapped due to divisions within their caucus